US$ 27.64
sglt2 inhibitors vs glp 1 agonists SGLT-2 and GLP-1 Agonists: First-Line Therapy for Diabetes With Established Cardiovascular Disease Use of GLP-1 Receptor Agonists
Description
GLP-1 drugs

Indeed, GLP-1R agonism slows gastric emptying (51, 52) and suppresses small intestinal motility (53)

Ferreira JP, Mehta C, Sharma A, Nissen SE, Rossignol P, Zannad F

Initial authorization is usually given for 6-8 months

These findings indicate a dissociation in the modulation of DPP-4-related parameters and inflammatory biomarkers in humans [32, 33]

However, emerging evidence suggests that stopping therapy often leads to weight regain, reinforcing the concept of obesity as a chronic condition requiring ongoing pharmacologic support
